Last10K.com

Inspyr Therapeutics, Inc. (NSPX) SEC Filing 8-K Material Event for the period ending Tuesday, September 12, 2017

Inspyr Therapeutics, Inc.

HISTORY TOOLS
CIK: 1890671 Ticker: NSPX

View differences made from one to another to evaluate Inspyr Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inspyr Therapeutics, Inc..

Continue

Assess how Inspyr Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inspyr Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools
Ticker: NSPX
CIK: 1421204
Form Type: 8-K Corporate News
Accession Number: 0001615774-17-005119
Submitted to the SEC: Fri Sep 15 2017 4:01:57 PM EST
Accepted by the SEC: Fri Sep 15 2017
Period: Tuesday, September 12, 2017
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/nspx/0001615774-17-005119.htm